Chao-Hung Hung
Chang Gung University
Internal medicineVirologyImmunologyHazard ratioHBeAgEntecavirHepatitis C virusHepatitis CCirrhosisHepatitis BHBsAgHepatocellular carcinomaRibavirinHepatitis B virusChronic hepatitisIncidence (epidemiology)MedicineGastroenterology
Publications 250
#1Chung-Feng HuangH-Index: 23
#2Hsing-Tao KuoH-Index: 6
Last. Cheng-Yuan PengH-Index: 32
view all 43 authors...
#1Cih-En Huang (CGU: Chang Gung University)H-Index: 11
#2Jung-Jung Chang (Memorial Hospital of South Bend)H-Index: 1
Last. Kuan-Der Lee (TMU: Taipei Medical University)
view all 12 authors...
BACKGROUND Thrombocytopenia is a common extrahepatic manifestation in chronic liver disease. However, there have been rare studies of impacts of risk for hepatitis C virus-associated thrombocytopenia (HCV-TP) and hepatitis B virus-associated thrombocytopenia (HBV-TP). The aim of this study is to evaluate different impacts of risk factors for HCV-TP and HBV-TP. MATERIAL AND METHODS We retrospectively collected 1803 HCV patients and 1652 HBV patients to examine the risk factors for time to moderat...
#1Ming Lun Yeh (KMU: Kaohsiung Medical University)H-Index: 6
#2Chao-Hung Hung (Memorial Hospital of South Bend)H-Index: 46
Last. Rong-Nan Chien (Memorial Hospital of South Bend)H-Index: 19
view all 39 authors...
The long-term outcome of hepatitis B virus (HBV) infection among patients dually infected with HBV and hepatitis C virus (HCV) remains unclear. We aimed to investigate the long-term liver outcomes of HBV/HCV-coinfected patients after antiviral therapy. A total of 11,359 chronically HCV-infected patients with interferon-based therapy were registered in a nationwide Taiwanese Chronic Hepatitis C Cohort. A propensity score matched (PSM) cohort of HCV mono-infected (n = 7020) and HBV/HCV (n = 702) c...
#1Chung-Feng Huang (KMU: Kaohsiung Medical University)H-Index: 23
#2Kuo-Chih Tseng (TCU: Tzu Chi University)H-Index: 5
Last. Pei-Lun LeeH-Index: 3
view all 48 authors...
Background & Aims null Sofosbuvir is approved for chronic hepatitis C (CHC) patients with severe chronic kidney disease (CKD). The impact of sofosbuvir-based therapy on renal function augmentation on a real-world nationwide basis is elusive. null null null Methods null The 12,995 CHC patients treated with sofosbuvir-based (n = 6802) or non–sofosbuvir-based (n = 6193) regimens were retrieved from the Taiwan nationwide real-world HCV Registry Program. Serial estimated glomerular filtration rate (e...
#1Hsin-Yeh Chen (CGU: Chang Gung University)
#2Kwong-Ming Kee (CGU: Chang Gung University)H-Index: 21
Last. Yuan-Hung Kuo (CGU: Chang Gung University)H-Index: 17
view all 8 authors...
Background/Purpose null This study is to use albumin-bilirubin (ALBI) grade and up-to-7 (UT7) criteria to assess outcomes of patients with intermediate stage hepatocellular carcinoma (HCC) after transarterial (chemo)embolization (TA(C)E). null null null Methods null Between January 2012 and January 2019, newly diagnosed intermediate HCC patients underwent TA(C)E were enrolled and analyzed. The demographics, clinical characteristics and survival were obtained from medical chart reviews. null null...
#1Yen-Po Lin (CSMU: Chung Shan Medical University)
#2Shu-Hsien Lin (CGU: Chang Gung University)
Last. Wei-Ru Cho (CGU: Chang Gung University)H-Index: 1
view all 12 authors...
Backgrounds and Aim: Metabolic-associated fatty liver dis-ease (MAFLD) is a novel term proposed in 2020 to avoid the exclusion of certain subpopulations, though the application of this term in the real world is very limited. Here, we aimed to evaluate the impact of MAFLD on hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative resection. Methods: Patients with chronic hepatitis B (CHB)-related HCC who received hepatectomy between January 2010 and December 2019 were consec...
#1Hsin-Wei Fang (CGU: Chang Gung University)
#2Yi-Hao Yen (CGU: Chang Gung University)H-Index: 21
Last. Chien-Hung Chen (CGU: Chang Gung University)H-Index: 36
view all 7 authors...
The predictors of persistent virological suppression after clinical relapse remain unclear. To investigate the predictors of retreatment or persistent virological suppression after clinical relapse in chronic hepatitis B (CHB) patients who discontinued entecavir or tenofovir disoproxil fumarate (TDF). A total of 243 hepatitis B e antigen-negative CHB patients without cirrhosis who experienced clinical relapse after entecavir or TDF cessation were enrolled. Of the 243 CHB patients, 192 received r...
#1Kao-Chi ChangH-Index: 2
#2Shui-Yi TungH-Index: 7
Last. Huang-Wei XuH-Index: 3
view all 14 authors...
#1Yu-Chi Lee (CGU: Chang Gung University)H-Index: 1
#2Jing-Houng Wang (CGU: Chang Gung University)H-Index: 54
Last. Yuan-Hung Kuo (CGU: Chang Gung University)H-Index: 17
view all 10 authors...
Sorafenib is the recommended first-line treatment option for patients with advanced hepatocellular carcinoma (HCC). Hepatitis C virus (HCV)-related advanced HCC (HCV-HCC) seemed to have a better response than hepatitis B virus (HBV)-related HCC (HBV-HCC) in sorafenib use, but it was undetermined. Hence, we aimed to investigate the effect of sorafenib between HBV-HCC and HCV-HCC patients in Taiwan. From August 2012 to December 2016, 575 consecutive advanced HCC patients received sorafenib under t...